AQR Capital Management
DFTX

AQR Capital Management’s Definium Therapeutics DFTX Stock Holding History

AQR Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Sell
57,094
-1,204
-2% -$20.4K ﹤0.01% 2722
2025
Q4 		$781K Buy
58,298
+36,702
+170% +$454K ﹤0.01% 2688
2025
Q3 		$255K Buy
21,596
+1,838
+9% +$17.1K ﹤0.01% 3158
2025
Q2 		$128K Buy
19,758
+7,508
+61% +$49.4K ﹤0.01% 3136
2025
Q1 		$71.7K Sell
12,250
-12,887
-51% -$92.3K ﹤0.01% 3061
2024
Q4 		$175K Buy
25,137
+2,364
+10% +$16.3K ﹤0.01% 2698
2024
Q3 		$130K Buy
+22,773
New +$158K ﹤0.01% 2628

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management's DFTX Position: Q1 2026 in Review

AQR Capital Management reduced its Definium Therapeutics (DFTX) stake by 2.1% in Q1 2026, selling an estimated $20.4K and leaving 57,094 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

AQR Capital Management first reported a position in DFTX in Q3 2024 and has held it in 7 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • AQR Capital Management held 57,094 shares of Definium Therapeutics worth $1.08M as of Q1 2026.
  • AQR Capital Management sold 1,204 Definium Therapeutics shares in Q1 2026, an estimated $20.4K.
  • Definium Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2722 holding.
  • AQR Capital Management first reported a position in Definium Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.